ImmuneSensor Therapeutics focuses on leveraging the body's innate immune system to develop new treatments for various diseases. By targeting the cGAS-STING pathway, the company aims to stimulate immune responses for cancer therapy and suppress overactivated autoimmunity. ImmuneSensor has licensed technologies from Dr. Zhijian "James" Chen, a renowned molecular biology professor, whose discoveries form the foundation of the company. Their pipeline includes STING activators to enhance anticancer immunity and cGAS inhibitors to manage autoimmune conditions. Their leading program, IMSA101, is a STING activator currently in clinical development for cancer treatment.